Advanced in Pulmonary Hypertension

Kuo-yang J. Wang

Taitung, TNQ, TW 
Advanced in Pulmonary Hypertension
Taitung, TNQ, TW 
OverviewLocationsClinical Research

Overview

Kuo-yang Wang practices in Taitung, Taiwan. Wang is rated as an Advanced expert by MediFind in the treatment of Pulmonary Hypertension. Their top areas of expertise are Pulmonary Hypertension, Hypertension, Cor Triatriatum, Stent Placement, and Lung Transplant.

Their clinical research consists of co-authoring 53 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 14 articles and participated in 2 clinical trials in the study of Pulmonary Hypertension.

Locations

Taitung, TNQ, Taiwan
Other Locations
TPQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

53 Total Publications

A risk stratification model modified from the U.S. guideline could be applied in an Asian population with or without ASCVD: Validation study.
A risk stratification model modified from the U.S. guideline could be applied in an Asian population with or without ASCVD: Validation study.
Journal: Biomedical journal
Published: April 28, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wang's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile